Waystar Weighs Sale Amidst Decline in Market Value, Sources Reveal

Waystar, a prominent player in healthcare software, is reportedly exploring strategic alternatives, including a potential sale, according to multiple sources familiar with the situation. This move comes just two years after the company's initial public offering on the New York Stock Exchange.

Waystar's Strategic Shift

Headquartered in Lehi, Utah, and Louisville, Kentucky, Waystar provides technology solutions for healthcare administrative tasks, such as payment management for hospitals and physicians. The company has positioned itself as a technology entity rather than a traditional services company, aiming to attract higher valuations typically associated with tech firms. Despite initial investor enthusiasm, Waystar's market value has recently fallen to approximately $4.8 billion, following a 24% decline in its share price this year.

Investment Bank Evercore Engaged

Waystar has engaged investment bank Evercore to advise on the potential sale process, which is in its early stages. Sources, opting for anonymity due to the confidentiality of the discussions, indicated that there is no certainty a sale will occur. Evercore has not commented on the matter, and Waystar has also declined to provide any statements.

Market Conditions and Investor Concerns

The company's declining stock performance reflects broader challenges in the software sector, exacerbated by investor concerns over the impact of artificial intelligence on traditional software business models. Despite reaching a peak share price of $45 in 2025, Waystar's stock has since experienced significant pressure.

Ownership and Financial Backing

Waystar emerged from the 2017 merger of Zirmed and Navicure, both healthcare revenue management firms. The company went public in 2024, with major investors including EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. EQT holds the largest stake at 13%, followed by CPPIB with 10%, and BlackRock Institutional Trust Company with 8%.

While EQT and BlackRock have declined to comment on the sale exploration, CPPIB has not yet responded to requests for comment. The outcome of Waystar's strategic review remains uncertain, and industry observers are closely watching to see if investor interest in software companies will rebound.